Iterum Therapeutics plc

A securities class action has been filed against Iterum Therapeutics plc (ITRM) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Iterum securities between November 30, 2020 through July 23, 2021. This case has been filed in the USDC – N.D.IL.

Iterum Therapeutics stock prices from November 2020 to June 2021

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the sulopenem NDA lacked sufficient data to support approval for the treatment of adult women with uUTIs caused by designated susceptible microorganisms proven or strongly suspected to be non-susceptible to a quinolone; (ii) accordingly, it was unlikely that the FDA would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.